Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition-Reference-Cited by-同舟云学术

Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition

Published:2021-06-03 Issue:16 Volume:27 Page:4610-4623
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Annala Matti,Taavitsainen Sinja,Khalaf Daniel J.^ORCID,Vandekerkhove Gillian^ORCID,Beja Kevin,Sipola Joonatan,Warner Evan W.,Herberts Cameron^ORCID,Wong Amanda,Fu Simon^ORCID,Finch Daygen L.,Oja Conrad D.,Vergidis Joanna,Zulfiqar Muhammad,Eigl Bernhard J.^ORCID,Kollmansberger Christian K.,Nykter Matti,Gleave Martin E.,Chi Kim N.,Wyatt Alexander W.^ORCID

Funder

Academy of Finland

Terry Fox Research Institute

Prostate Cancer Foundation

Gouvernement du Canada | CIHR | Institute of Cancer Research

Prostate Cancer Canada

Canadian Cancer Society

Jane ja Aatos Erkon Säätiö

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial;Nature Medicine;2024-08-20

2. DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes;JCO Precision Oncology;2024-08

3. PROTACing the androgen receptor and other emerging therapeutics in prostate cancer;Expert Review of Anticancer Therapy;2024-07-22

4. Impact of Novel Agents on Patient Characteristics, Treatment Patterns, and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer;Anticancer Research;2024-06-26

5. Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications;Cancers;2024-06-20